# Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism

> **NCT01220050** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 43 (actual)

## Conditions studied

- Renal Transplant
- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Paricalcitol
- **DRUG:** Standard therapy

## Key facts

- **NCT ID:** NCT01220050
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-07
- **Final completion:** 2013-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220050, "Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01220050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*